Get startedLog in
    Picture of Immunoprecise Antibodies logo

    IPA — Immunoprecise Antibodies Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Immunoprecise Antibodies, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.

    2019
    April 30th
    2020
    April 30th
    2021
    April 30th
    2022
    April 30th
    2023
    April 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-7.62-4.95-7.34-16.7-26.6
    Depreciation
    Deferred Taxes
    Non-Cash Items2.151.724.132.774.24
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital0.581-1.12-1.020.582-3.28
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Net Change in Other Assets & Liabilities
    Cash from Operating Activities-3.21-1.39-0.6-9.92-19.8
    Capital Expenditures-0.645-0.488-1.38-1.07-1.5
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-1.56-1.1-1.08-4.14-0.472
    Acquisition of Business
    Sale/Maturity of Investment
    Other Investing Cash Flow
    Cash from Investing Activities-2.2-1.58-2.46-5.21-1.97
    Financing Cash Flow Items-0.2880—-0.0050
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities9.350.17543.42.88-0.621
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash3.73-2.8539.1-11.8-21.7